National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Economic Evaluation of cabazitaxel (Jevtana®) for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with docetaxel-containing treatment regimen.

Rapid Review

Commenced Completed Outcome
02/06/2011 09/06/2011 Full Pharmacoeconomic Evaluation Recommended.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
03/11/2011 13/03/2012 Reimbursement not recommended at the submitted price.

The NCPE believe that, at the submitted price, cabazitaxel is not cost-effective for the treatment of patients with mHRPC previously treated with a docetaxel-containing treatment regimen.

Cabazitaxel (Jevtana®) Summary

March 2014

The HSE has approved reimbursement following confidential price negotiations.